What was recalled
The U.S. Food and Drug Administration has issued a Class II recall involving a specific pharmaceutical ingredient manufactured by Shoolin Pharma Chem LLP, a company based in Gujarat, India. This is not a finished consumer pill you might pick up at a local pharmacy counter, but rather a raw chemical substance intended for professional use only. The product in question is Sildenafil Citrate USP, identified by National Drug Code (NDC) 85702-001-08. It is packaged in 1.00-kilogram bags with a net weight of exactly 1.00KG per bag. The packaging clearly states "Rx only" and includes the critical disclaimer "For Prescription Compounding Only," indicating that this material is meant to be processed by pharmacists or compounding specialists, not sold directly to patients for immediate use.
The specific batch affected by this recall is Lot number SDC2505001. This lot carries an expiration date of April 30, 2030, which means the product was still within its shelf life when the issue was identified. The manufacturer’s address is listed as Block/Survey no 408, B/H Ratnamani Tubes, Near Maruti Inox, Indrad, Kadi, Mahesania, Gujarat, 382715, India. While the manufacturing origin is international, the distribution pattern for this specific lot was nationwide across the United States. This wide distribution network underscores the importance of verifying whether your compounding facility or pharmacy received inventory from this particular supplier and lot.
The recall was officially announced on August 3, 2026. It stems from Current Good Manufacturing Practice (CGMP) deviations noted during an FDA inspection. CGMP standards are the federal guidelines that ensure pharmaceutical products are consistently produced and controlled to quality standards. When these deviations occur, it raises concerns about the purity, strength, quality, or purity of the drug substance, even if the product has not yet been turned into a final prescription for a patient. The specific nature of these CGMP deviations is not detailed in the public record beyond the general classification, but such findings typically relate to processes that could compromise the integrity of the chemical compound.
It is important to note that the remedy for this recall has not been explicitly stated in the available information. Typically, Class II recalls involve products that might cause temporary health problems or pose a slight threat of serious disease, and the agency works with companies to remove these items from the supply chain. However, without a specific remedy listed, such as a return-to-manufacturer process or destruction protocol, stakeholders must rely on general guidance for handling potentially non-compliant drug substances. If you are a compounding pharmacy or healthcare provider who purchased this item, you should immediately contact your supplier and consult with legal or regulatory counsel to determine the proper disposal or return procedures, as standard consumer return policies do not apply to bulk pharmaceutical ingredients.
The CAS Number for Sildenafil Citrate is 171599-83-0, which serves as a unique chemical identifier. This detail helps in accurately tracking the substance across databases and supply chains. Because this is an active pharmaceutical ingredient rather than a finished good, the risk is primarily to those who process it. For the general public, the impact is indirect; however, anyone who receives a compounded prescription from a facility that may have used this lot should be aware of the potential issue. The recall highlights the complex nature of global pharmaceutical supply chains and the rigorous oversight required to maintain safety standards from the raw material stage all the way to the patient.
The hazard, explained
In this specific recall, the U.S. Food and Drug Administration (FDA) has identified a critical issue regarding current Good Manufacturing Practices (CGMP). While the official notice does not list a specific chemical defect or contamination event, it flags that "CGMP Deviations" were noted during an FDA inspection of the manufacturing facility. To understand why this matters, it is helpful to look at what CGMP actually means and how its absence creates risk in pharmaceutical production.
Current Good Manufacturing Practices are a system designed to ensure that products are consistently produced and controlled according to quality standards. Think of CGMP as the rigorous rulebook for a pharmaceutical factory. It dictates everything from the cleanliness of the room where Sildenafil Citrate is processed, to how equipment is calibrated, how raw materials are tested, and exactly who signs off on each batch. When an agency like the FDA notes "CGMP deviations," it means that one or more of these essential safety checks were skipped, performed incorrectly, or documented improperly during the production of this specific lot (SDC2505001) of Sildenafil Citrate USP.
The physical mechanism of harm here is not always a visible flaw like discoloration. Instead, the risk stems from unpredictability. Sildenafil Citrate is a potent active pharmaceutical ingredient used to treat pulmonary arterial hypertension and erectile dysfunction. Because it is labeled "For Prescription Compounding Only," it is intended to be mixed by pharmacists into final dosages for patients. If CGMP standards were violated during its creation at the Shoolin Pharma Chem LLP facility in Gujarat, India, several invisible problems could exist:
- Potency Variance: The concentration of the active drug may not be exactly what is listed on the label. It might be too weak to provide therapeutic benefit, or dangerously strong, leading to overdose symptoms such as severe hypotension (dangerously low blood pressure), vision changes, or priapism.
- Purity Issues: Deviations in manufacturing can allow unwanted byproducts or impurities to remain in the final powder. These impurities are not part of the approved formula and could cause unexpected allergic reactions or toxic effects when compounded into medication.
- Contamination Risks: If environmental controls (like air filtration or surface sterilization) were compromised, the bulk powder could harbor microscopic contaminants, including bacteria or fungal spores. When a pharmacist uses this material to compound prescriptions, those contaminants are transferred directly to the patient.
The reason this is classified as a Class II recall is significant. A Class II classification indicates that use of the product might cause temporary, or medically reversible, health problems, or pose a slight threat of serious harm. It suggests that while the risk is not immediately fatal for most people, it is substantial enough to warrant regulatory intervention because patients cannot know which bags contain compliant material and which do not. Without strict adherence to CGMP, there is no guarantee that this 1.00KG bag contains pure Sildenafil Citrate as declared by its CAS number (171599-83-0). The uncertainty itself is the hazard.
Who is most at risk
To understand who faces the greatest potential concern in this specific recall, we first need to look closely at what was recalled and how it is intended to be used. The product involved is Sildenafil Citrate USP, a prescription-only medication primarily known for treating erectile dysfunction and pulmonary arterial hypertension. However, the critical detail here is that this particular batch was labeled "For Prescription Compounding Only." This classification significantly shifts the risk profile away from the end consumer who might buy a pre-made tablet at a pharmacy counter. Instead, the primary individuals interacting with this product are healthcare professionals—specifically pharmacists and compounding specialists—and the patients they serve.
The hazard associated with this recall is not an immediate toxic contamination or a known adverse event, but rather "CGMP Deviations" (Current Good Manufacturing Practice deviations) noted during an FDA inspection. While the recall facts do not specify exactly which quality standards were missed, CGMP deviations generally relate to failures in the manufacturing environment, such as improper handling, inadequate testing, poor documentation, or contamination risks during production. For a drug like Sildenafil, which is often compounded into customized doses for patients who cannot swallow standard pills or require specific dosages, consistency and purity are paramount. Therefore, the individuals most at risk are those who rely on the precise potency and sterility of this compounded medication.
Patients who are elderly or have complex medical histories may be disproportionately affected if the manufacturing deviations resulted in inconsistent drug strength. If the Sildenafil Citrate was under-dosed, patients relying on it for pulmonary arterial hypertension might not receive adequate relief, potentially leading to worsening respiratory symptoms or decreased quality of life. Conversely, if the product was over-potentiated, even a small error in compounding could lead to dangerous drops in blood pressure, particularly in elderly patients who may already be taking other medications that interact with Sildenafil, such as nitrates for heart conditions. This group is especially vulnerable because their bodies often metabolize drugs more slowly, making them less tolerant to fluctuations in medication quality.
Furthermore, individuals with compromised immune systems or those managing chronic cardiovascular issues should exercise heightened caution. While there were no reported incidents of injury listed in the recall notice, the uncertainty surrounding the manufacturing process means that trace contaminants or inconsistent active ingredients could pose unexpected health risks. These patients often have less physiological reserve to handle unexpected side effects or adverse reactions. It is also important to note that while the distribution was nationwide, the risk is not uniform across all Americans. The risk is concentrated entirely within the supply chain of compounding pharmacies that received this specific lot (SDC2505001) from Shoolin Pharma Chem LLP. The general public who have never had a prescription filled at a specialty compounding pharmacy for this exact ingredient faces no direct risk from this recall.
In summary, the people most at risk are not casual users of over-the-counter supplements, but rather patients currently undergoing specialized treatment plans that require compounded Sildenafil Citrate. They depend on their healthcare providers to filter out unsafe products. If you or a loved one is in this situation, the priority is not panic, but verification. The risk is manageable as long as the specific lot number is identified and the medication is removed from use before any further compounding or administration occurs.
How to tell if you have the recalled item
Identifying whether a product is part of this specific FDA recall requires careful attention to several precise details. Because this recall involves a bulk pharmaceutical ingredient rather than a finished consumer drug, your verification process will look different depending on who you are and how you obtained the material. The primary step is to locate the physical packaging or documentation associated with the item in question. For anyone handling this product, whether you are a compounding pharmacy, a distributor, or a healthcare provider, the first thing to check is the label. You need to look for the brand name "Shoolin Pharma Chem" prominently displayed. This is the manufacturer responsible for the batch under review, and confirming this identity is your initial filter.
Once you have confirmed the brand, you must verify the exact product description and specifications. The recalled item is specifically identified as SILDENAFIL CITRATE USP. It is crucial to note that this is a raw chemical ingredient, not a finished tablet or capsule for direct patient use. The packaging should clearly state "For Prescription Compounding Only" and indicate that it is an Rx-only substance. In terms of physical quantity, the recall applies to units packaged in 1.00KG bags with a net weight of 1.00KG. If you are holding a container of a different size or weight, it may not be part of this specific recall lot, but you should still verify other details just to be safe.
The most critical step for definitive identification is checking the lot number and the National Drug Code (NDC). You must look for NDC 85702-001-08 on the label or the accompanying certificate of analysis. This code is unique to this specific product configuration and helps distinguish it from other sildenafil products on the market. Alongside the NDC, you must find the lot number SDC2505001. If the lot number does not match exactly, the item is not part of this recall. Additionally, check the expiration date, which should be listed as April 30, 2030. While a future expiration date might seem reassuring, it does not negate the quality control issues that triggered the Class II classification.
If you are unable to find physical labels, such as when reviewing digital invoices or supply chain records, look for these same identifiers in your documentation. The supplier information should list Shoolin Pharma Chem LLP, located at Block/Survey no 408, B/H Ratnamani Tubes, Near Maruti Inox, Indrad, Kadi, Mahesania, Gujarat, 382715, India. The CAS number for the chemical is 171599-83-0. Since the distribution pattern was nationwide across the USA, there is no geographic restriction that can help you rule out the product based on location alone. If you have any of these specific identifiers, particularly the lot number SDC2505001 and NDC 85702-001-08, you should consider the item recalled and take immediate steps to secure it.
What to do — step by step
If you are a pharmacy, compounding facility, or healthcare provider that may have received the Sildenafil Citrate USP distributed by Shoolin Pharma Chem LLP, your first and most critical action is to immediately stop using this product. The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations identified during an FDA inspection. While the specific nature of these deviations is not detailed in the public recall notice, CGMP violations are serious because they indicate that the manufacturing environment or processes did not meet the strict quality and safety standards required for pharmaceutical products. This means there is a risk that the potency, purity, or sterility of the drug could be compromised. Therefore, you must quarantine any remaining inventory of Sildenafil Citrate USP (NDC 85702-001-08), specifically Lot SDC2505001 with an expiration date of April 30, 2030, in a secure area to prevent it from being accidentally dispensed or used. Do not attempt to test the product yourself or mix it with other supplies.
The FDA recall notice does not currently state a specific remedy, such as a mandatory return process, a direct refund mechanism, or instructions for repair or replacement. This is not uncommon in Class II recalls involving raw pharmaceutical ingredients where the primary regulatory focus is on stopping distribution and preventing use rather than managing consumer returns. Because there is no official return address or customer service hotline listed in the recall data, you should not wait for further instructions if you suspect you have stock. Instead, you must proactively contact your supplier or distributor to arrange for the disposal or return of the product according to their internal policies. It is also advisable to notify your procurement department and quality assurance team immediately so they can document the issue and trace any potentially affected compounded prescriptions.
If you are a patient who has already received medication compounded from this specific lot, do not panic, but act with caution. Since the ingredient was flagged for manufacturing deviations, you should contact the pharmacy that filled your prescription immediately. Explain that the facility received a Class II recall notice for Sildenafil Citrate (Lot SDC2505001). The pharmacy will need to verify if they used this specific lot and will likely advise you to stop taking the medication and return it for proper disposal. They may also coordinate with their wholesaler to replace your prescription with product from a verified, non-recalled lot. Do not dispose of the medication in your household trash or down the drain unless instructed by local hazardous waste guidelines; pharmacies often have take-back programs for safe disposal.
Finally, stay informed. Recall situations can evolve, and additional details may be released by the FDA or the company later. Monitor the FDA’s official website for updates on this specific recall (Shoolin Pharma Chem LLP). Keep records of all communications with your pharmacy or supplier, including dates, names of representatives spoken to, and any reference numbers provided. This documentation is important for both your safety record and for any potential administrative follow-up. Remember that while Class II recalls are not typically associated with severe health consequences, they indicate a potential threat to health if the product is used, so treating this situation with urgency and care is the safest path forward.
Your refund, repair, or replacement options
When you encounter a product recall, the most immediate and practical question is often, "What happens next regarding my money or the item itself?" In this specific case involving Shoolin Pharma Chem LLP’s Sildenafil Citrate USP, it is important to approach the situation with clarity and calm. The official FDA recall documentation for this Class II hazard does not explicitly state a standardized remedy such as a direct refund, a repair service, or a replacement unit. This absence of stated terms can feel uncertain, but it is a common scenario in pharmaceutical recalls where the primary focus is on removing the product from the supply chain to ensure patient safety rather than processing consumer transactions.
To understand why this is the case, we must look at the nature of the recalled item. The product in question is "SILDENAFIL CITRATE USP," a bulk pharmaceutical ingredient supplied in 1.00KG bags. Crucially, the labeling specifies that it is "Rx only" and "For Prescription Compounding Only." This means this product is not a finished consumer good sold directly to individuals at a pharmacy counter. Instead, it is an active pharmaceutical ingredient (API) intended for use by licensed pharmacists or compounding pharmacies who prepare customized medications for patients. Because these transactions occur between businesses (B2B) rather than between a company and a general retail consumer, the standard "return to sender" or "refund to credit card" processes you might expect from a consumer electronics recall do not apply in the traditional sense.
If you are a compounding pharmacy that received this material, your path forward is administrative rather than transactional. You should immediately cease using the product and isolate it to prevent any accidental dispensing. Your next step should be to contact the distributor or supplier through whom you originally purchased Lot SDC2505001 (NDC 85702-001-08). They will coordinate with Shoolin Pharma Chem LLP to arrange for the return of the goods. The financial reconciliation—whether that results in a credit memo, a refund, or a replacement shipment of compliant stock—will be handled privately between your pharmacy and their vendor. This is standard industry practice for bulk chemical deviations.
If you are a patient who was prescribed a medication compounded from this specific lot, please do not attempt to return the bag yourself. You cannot return a 1.00KG industrial bag of raw chemical powder through normal consumer channels. Instead, contact your pharmacy immediately. They have a legal and ethical obligation to verify their inventory against recall notices. If they used this lot in any medication dispensed to you, they will notify you directly to stop taking the medication and provide instructions for safe disposal or replacement. Any financial adjustments regarding the cost of that prescription will be handled by your pharmacy’s billing department in accordance with their insurance policies and the supplier's credit terms.
In summary, while a direct refund portal or customer service number is not listed in the public recall data because this is a specialized B2B pharmaceutical ingredient, the financial remedy exists within the commercial relationship between the pharmacy and Shoolin Pharma Chem LLP. Your role, if you are an end-user, is to communicate with your healthcare provider or pharmacist, who will manage the logistical and financial aspects of the remedy on your behalf.
What can happen if you ignore it
When a pharmaceutical product is recalled due to Current Good Manufacturing Practice (CGMP) deviations, the risk isn't always immediate or dramatic like a contaminated batch causing an allergic reaction. Instead, the danger lies in the subtle, cumulative uncertainty of quality control. In this specific case involving Shoolin Pharma Chem LLP’s Sildenafil Citrate USP, the FDA identified deviations during an inspection. While the recall classification is Class II—indicating that use of the product might cause temporary health problems or pose a slight threat of a serious nature—the underlying issue is that the manufacturing process did not meet federal standards for consistency, strength, purity, and quality.
If you continue to use this medication without addressing the recall, you are essentially gambling with the reliability of your treatment. Sildenafil Citrate is a potent drug typically used to treat erectile dysfunction or pulmonary arterial hypertension. Its therapeutic window—the range between an effective dose and a harmful one—can be narrow. CGMP deviations mean that the powder you received may not contain exactly what the label claims. It could be under-potent, meaning it fails to provide the necessary relief, leading to treatment failure and potential frustration or delayed medical care for underlying conditions. Conversely, and perhaps more dangerously, it could be over-potent. An unexpectedly high concentration of the active ingredient can lead to severe side effects, including dangerously low blood pressure, prolonged erections (priapism), vision changes, or cardiovascular strain.
Furthermore, manufacturing deviations often involve issues beyond just potency. They can include contamination from improper equipment cleaning, cross-contamination with other substances, or incorrect packaging that compromises the drug’s stability over time. Even if the expiry date listed on this lot is April 30, 2030, the integrity of the chemical structure may have been compromised during production. Ignoring the recall means you are continuing to ingest a substance whose safety profile is unknown. You might experience unexpected adverse reactions that are difficult to diagnose because they stem from an unstandardized product rather than a predictable physiological response to a known medication.
There is also the broader public health implication. While your individual risk depends on your specific health conditions and dosage, widespread use of non-compliant pharmaceuticals undermines the safety net designed to protect patients. By ignoring the recall, you contribute to the persistence of these defective products in the market, potentially delaying corrective actions by the manufacturer or regulatory bodies. The most prudent course is to treat this deviation as a significant red flag. Your health and peace of mind are worth more than the inconvenience of returning a product; ensure that your treatment plan is adjusted with fresh, verified medication from a compliant source.
Staying safe: broader tips
When dealing with pharmaceutical products, particularly those intended for professional compounding rather than direct consumer use, vigilance is your most effective tool for ensuring safety. While this specific recall highlights a deviation from Current Good Manufacturing Practice (CGMP) standards by Shoolin Pharma Chem LLP, the broader lesson applies to anyone handling or prescribing medications. The integrity of a drug’s manufacturing process is just as critical as its chemical composition. Deviations in quality control can introduce contaminants, incorrect dosages, or stability issues that are not visible to the naked eye. Therefore, establishing robust verification habits with your healthcare providers and pharmacists is essential for long-term safety.
One of the most practical steps you can take is to maintain open communication with your prescriber about the source of your medications. If you are receiving compounded drugs, ask your pharmacist where the active pharmaceutical ingredients (APIs) originate. Reputable compounding pharmacies typically have strict vendor qualification processes and can provide documentation verifying that their suppliers adhere to rigorous FDA standards. Understanding the supply chain helps you feel more confident in the product’s consistency and purity. Additionally, never hesitate to report any unusual physical characteristics of a medication—such as unexpected discoloration, odor, or texture—to your pharmacist immediately.
Regularly checking for official recalls is another vital habit. Many people do not realize that drug recalls can happen at various stages, from manufacturing to distribution, and are often initiated proactively by manufacturers upon discovering potential issues. You can stay informed by signing up for email alerts on the FDA’s website or downloading their official mobile application. These tools provide timely updates on safety concerns across a wide range of products, allowing you to act quickly if your specific medication is affected. By staying connected to these official channels, you empower yourself with knowledge rather than relying solely on passive notification.
Finally, proper storage and handling of medications at home play a significant role in maintaining their efficacy and safety. Even if a product passes all manufacturing checks, improper storage conditions can degrade its quality over time. Always follow the specific storage instructions provided by your pharmacist, which may include requirements for temperature control, protection from light, or humidity prevention. For compounded medications, which often lack the extensive preservative systems found in mass-produced drugs, adhering to expiration dates and storage guidelines is particularly crucial. By combining diligent storage practices with active engagement in safety monitoring, you create a comprehensive shield against potential risks associated with pharmaceutical products.